Aigen Investment Management LP Sells 1,351 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Aigen Investment Management LP trimmed its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 16.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,632 shares of the medical device company’s stock after selling 1,351 shares during the quarter. Aigen Investment Management LP’s holdings in Cooper Companies were worth $732,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of COO. Innealta Capital LLC acquired a new position in shares of Cooper Companies during the second quarter worth approximately $25,000. Ashton Thomas Securities LLC acquired a new position in Cooper Companies in the third quarter valued at approximately $25,000. Covestor Ltd lifted its holdings in Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after buying an additional 208 shares during the period. Crewe Advisors LLC lifted its holdings in Cooper Companies by 286.4% in the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after buying an additional 252 shares during the period. Finally, Tortoise Investment Management LLC lifted its holdings in Cooper Companies by 75.4% in the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after buying an additional 169 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

COO has been the topic of several analyst reports. Morgan Stanley increased their price objective on shares of Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a report on Tuesday, September 10th. Stifel Nicolaus restated a “buy” rating and issued a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. StockNews.com upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Thursday. Robert W. Baird increased their price objective on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. Finally, Wells Fargo & Company upped their target price on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

Cooper Companies Stock Down 0.1 %

Shares of COO stock opened at $101.88 on Thursday. The firm has a fifty day moving average of $107.10 and a 200-day moving average of $97.85. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The Cooper Companies, Inc. has a 12-month low of $82.21 and a 12-month high of $112.38. The company has a market capitalization of $20.29 billion, a price-to-earnings ratio of 56.76, a P/E/G ratio of 2.20 and a beta of 0.99.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.84 earnings per share. As a group, equities research analysts predict that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Insider Activity at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of the firm’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the completion of the transaction, the chief executive officer now owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Albert G. White III sold 114,992 shares of the firm’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the completion of the transaction, the chief executive officer now owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian G. Andrews sold 24,788 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the sale, the chief financial officer now owns 6,614 shares of the company’s stock, valued at approximately $700,422.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 256,373 shares of company stock valued at $27,637,427. Corporate insiders own 2.00% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.